Abstract Number: 1772 • 2018 ACR/ARHP Annual Meeting
Apremilast in Refractory Oral and/or Genital Ulcers in Behçet’s Disease. Multicenter Study of 37 Cases
Background/Purpose: Behçet´s disease (BD) is characterized by recurrent oral and/or genital ulcers accompanied by ocular, cutaneous, articular, gastrointestinal, and/or neurologic manifestations. Oral and/or genital aphthous…Abstract Number: 1806 • 2018 ACR/ARHP Annual Meeting
Spinal Cord Involvement in Behcet’s Disease- Experience of a Vasculitis Centre at Silk Road
Background/Purpose: Spinal cord involvement may occur in the course Behcet's Disease (BD). It may present with distinct manifestations such as sphincter and/or sexual dysfunction. We…Abstract Number: 1773 • 2018 ACR/ARHP Annual Meeting
Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis Due to Behçet’s Disease. National Multicenter Study of 177 Cases
Background/Purpose: Uveitis is one of the major causes of disability of Behçet's disease (BD). According to the “Expert panel recommendations” (Ophthalmology. 2014; 121:785-96), anti-TNF therapy…Abstract Number: 1807 • 2018 ACR/ARHP Annual Meeting
Clinical Features and Disease Course of Neurologic Involvement in Behcet’s Disease
Background/Purpose: Neurological involvement (NBD) is a rare complication of BD. Although NBD is not common in the course of BD, it is related with significant…Abstract Number: 1778 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical and Angiographic Features of Arterial Involvement in Takayasu’s Arteritis and Behcet’s Disease
Background/Purpose: Systemic vasculitis is one of the major manifestations of Behcet’s disease (BD). Takayasu’s arteritis (TA) is a chronic vasculitis that primarily affects the aorta…Abstract Number: 1809 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics of Older Age-Onset Behçet Syndrome Patients
Background/Purpose: The usual onset of Behçet syndrome (BS) is in the 3. decade. Older age-onset defined as fulfilling the International Study Group (ISG) criteria after…Abstract Number: 2721 • 2017 ACR/ARHP Annual Meeting
Anti-IL6-Receptor Tocilizumab in Refractory Uveitis Associated to Extraocular Manifestations in Patients with Behçet’s Disease. Multicenter Study
Background/Purpose: To assess the efficacy of Tocilizumab (TCZ) in refractory uveitis associated to extraocular manifestations due to Behçet’s disease (BD). Methods: Multicenter study of patients…Abstract Number: 2722 • 2017 ACR/ARHP Annual Meeting
Long Term Follow-up and Optimization of Infliximab in Refractory Uveitis of Behçet’s Disease. Multicenter Study of 103 Cases
Background/Purpose: Uveitis is a severe manifestation of Behçet Disease (BD). The treatment is based on corticosteroids and conventional immunosuppressive drugs. In refractory cases, anti-TNFα had…Abstract Number: 2723 • 2017 ACR/ARHP Annual Meeting
Adalimumab Therapy Optimization in Refractory Uveitis Due to Behçet’s Disease after Achieving Remission. interventional Versus Control Group
Background/Purpose: Adalimumab (ADA) therapy has been approved by the EMA and the FDA in non-infectious and non-anterior uveitis. After loading, the maintenance dose is 40…Abstract Number: 2724 • 2017 ACR/ARHP Annual Meeting
Apremilast for Refractory Mucocutaneous Ulcers of Behçet’s Disease. National Multicenter Study of 14 Cases
Background/Purpose: Behçet´s disease (BD) is characterized by recurrent oral and/or genital ulcers accompanied by ocular, cutaneous, articular, gastrointestinal, and/or neurologic manifestations. Oral and/or genital aphthous…Abstract Number: 2728 • 2017 ACR/ARHP Annual Meeting
Serum Levels of Interleukin-36 Receptor Antagonist in Behçet’s Patients
Background/Purpose: Behcet's disease (BD) is a systemic vasculitis disorder of unknown etiology with recurrent exacerbations and remissions. The etiopathogenesis of the disease is still unclear.…Abstract Number: 2729 • 2017 ACR/ARHP Annual Meeting
Surgical Therapies in the Treatment of Pulmonary Artery Involvement in Behcet’s Syndrome
Background/Purpose: The mainstay treatment of pulmonary artery involvement (PAI) in Behcet’s syndrome (BS) is immunosuppresion and corticosteroids (1). The role of surgical intervention in the…Abstract Number: 2732 • 2017 ACR/ARHP Annual Meeting
Recommendations for the Management of Neuro-Behcet’s Disease By the Japanese National Research Committee for Behcet’s Disease
Background/Purpose: Central nervous system involvement is one of the most serious complications in Behçet’s disease (BD). This condition is referred to as neuro-Behçet’s disease (NB)…Abstract Number: 2744 • 2017 ACR/ARHP Annual Meeting
Long-Term Remission in Severe Behcet’s Disease Following Withdrawal of Successful Anti-TNF Treatment
Background/Purpose: Anti-TNF treatment has been shown to be effective in inducing complete remission in many Behcet’s disease (BD) patients with eye, large vessel, intestine and…Abstract Number: 2747 • 2017 ACR/ARHP Annual Meeting
Long Term Follow-up of Behcet’s Syndrome Patients Treated with Cyclophosphamide
Background/Purpose: Cyclophosphamide (CYC) remains an important treatment option for Behçet’s syndrome (BS) pts with life threatening conditions such as arterial aneurysms. However, several adverse events…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 12
- Next Page »